Piedmont Investment Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Piedmont Investment Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-21,290	Closed	-$99K	–	1357
2019 Q1	$99K	Buy	21,290 +1,175	+6%	+$5.32K	﹤0.01%	1130
2018 Q4	$84K	Buy	20,115 +788	+4%	+$4.01K	﹤0.01%	1014
2018 Q3	$121K	Buy	19,327 +2,141	+12%	+$16.4K	0.01%	1019
2018 Q2	$138K	Buy	17,186 +2,167	+14%	+$16.5K	0.01%	1002
2018 Q1	$112K	Buy	15,019 +576	+4%	+$3.83K	﹤0.01%	751
2017 Q4	$86K	Sell	14,443 -863	-6%	-$5.24K	﹤0.01%	753
2017 Q3	$113K	Buy	15,306 +122	+0.8%	+$775	﹤0.01%	757
2017 Q2	$103K	Buy	+15,184	New	+$112K	﹤0.01%	742

Other funds holding PGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Piedmont Investment Advisors's PGNX Position: Q2 2019 in Review

Piedmont Investment Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2019, closing a stake of 21,290 shares — an estimated $99K sold.

Piedmont Investment Advisors first reported a position in PGNX in Q2 2017 and held it in 8 quarters. The position peaked at $138K in Q2 2018. 142 funds tracked by Wall St. Rank hold PGNX as of Q2 2019.

Piedmont Investment Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2019 after selling out during the quarter.
Piedmont Investment Advisors sold 21,290 Progenics Pharmaceuticals Inc shares in Q2 2019, an estimated $99K.
Piedmont Investment Advisors first reported a position in Progenics Pharmaceuticals Inc in Q2 2017 and held it in 8 quarters.
Piedmont Investment Advisors's Progenics Pharmaceuticals Inc position peaked at $138K in Q2 2018.
142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2019.

Based on Piedmont Investment Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.